BMJ Open (Jul 2023)

An open-label pilot trial of faecal microbiome transfer to restore the gut microbiome in anorexia nervosa: protocol

  • José G B Derraik,
  • Wayne S Cutfield,
  • Karen S W Leong,
  • Benjamin B Albert,
  • Tommi Vatanen,
  • Justin M O'Sullivan,
  • Hiran Thabrew,
  • Brooke C Wilson,
  • Ry Y Tweedie-Cullen,
  • Christine Creagh,
  • Marysia Depczynski,
  • Taygen Edwards

DOI
https://doi.org/10.1136/bmjopen-2022-070616
Journal volume & issue
Vol. 13, no. 7

Abstract

Read online

Introduction Individuals with anorexia nervosa (AN) harbour distinct gut microbiomes compared with healthy individuals, which are sufficient to induce weight loss and anxiety-like behaviours when transplanted into germ-free mice. We hypothesise that faecal microbiome transfer (FMT) from healthy donors would help restore the gut microbiome of individuals with AN, which in turn, may aid patient recovery.Methods We aim to conduct an open-label pilot study in 20 females aged 16–32 years in Auckland, New Zealand who meet the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) criteria for AN and have a body mass index 13–19 kg/m2. We will recruit four healthy, lean, female donors, aged 18–32 years, who will undergo extensive clinical screening prior to stool donation. Faecal microbiota will be harvested from donors and double encapsulated in delayed release, acid-resistant capsules. All participants will receive a single course of 20 FMT capsules (five from each donor) which they can choose to take over two or four consecutive days. Stool and blood samples will be collected from participants over a period of 3 months to assess their gut microbiome profile, metabolome, levels of intestinal inflammation and nutritional status. Our primary outcome is a shift in the gut microbiome composition at 3 weeks post-FMT (Bray-Curtis dissimilarity). We will also monitor participants’ body composition (whole-body dual-energy X-ray absorptiometry scans), eating disorder psychopathology, mental health and assess their views on, and tolerability of, treatment. All adverse events will be recorded and reviewed by an independent data monitoring committee.Ethics and dissemination Ethics approval was provided by the Central Health and Disability Ethics Committee (Ministry of Health, New Zealand, 21/CEN/212). Results will be published in peer-reviewed journals and presented to both scientific and consumer group audiences.Trial registration number ACTRN12621001504808.